We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of 30 mg of Pioglitazone vs 4 mg of Rosiglitazone on Hyperglycemia and Dyslipidemia: Results from GLAI.
- Authors
Kupfer, Stuart; Spanheimer, Robert; Jacober, Scott; Tan, Meng; Gbenado, Seth
- Abstract
The hypothesis that the thiazolidinediones pioglitazone (PIO) and rosiglitazone (ROSI) have similar glucose-lowering effects but differing effects on lipids was supported by the GLAI study, which showed that PIO and ROSI lowered HbAlc to a similar extent, but that PIO was associated with more favorable changes in triglycerides (TG), HDL-C, and non-HDL-C. GLAI was a 6-month, randomized, double-blind trial in patients with type 2 diabetes (treated with diet or oral monotherapy only) and dyslipidemia (TG> 150, <600 mg/dL and LDL-C≤130 mg/dL); the primary variable of GLAI was change in TG, which was assessed in the absence of concomitant lipid-altering drugs. In GLAI, patients were assigned to treatment with PIO (N=369) or ROSI (N=366), both of which were titrated to their respective maximum effective dose: patients received 3 months of PIO 30 nag QD or ROSI 4 mg QD, followed by an additional 3 months of PIO 45 mg QD or ROSI 8 mg (4 mg BID). The purpose of this analysis was to evaluate the effectiveness of the starting doses of PIO (30 mg) and ROSI (4 mg) used in GLAI; therefore, change from baseline in lipid and HbA1c values were evaluated at month 3 (ie, before dose titration). Results of this analysis (see figure) revealed that, as observed for maximum doses, the starting doses of PIO and ROSI differed significantly in their effects on TG (P<0.001), HDL-C (P<0.001), and non-HDL-C (-6.53%±5.05 vs 12.67±5.33, respectively; P=0.003) in favor of PIO. However, unlike for the maximum doses, the 30 mg dose of PIO led to a significantly greater reduction in HbA1c than the 4 mg dose of ROSI (P=0.017). In summary, initial treatment with the 30 mg dose of PIO was more effective than use of the 4 mg dose of ROSI in terms of improving measures of hyperglycemia and dyslipidemia.
- Publication
Diabetes, 2007, Vol 56, pA542
- ISSN
0012-1797
- Publication type
Academic Journal